Summary & Overview
HCPCS J0886: Epoetin Alfa Injection, 1000 Units (ESRD on Dialysis)
HCPCS Level II code J0886 denotes an injection of epoetin alfa, 1000 units, for patients with end-stage renal disease (ESRD) on dialysis. This code captures the unit-based billing for erythropoiesis-stimulating therapy commonly administered during dialysis encounters to manage anemia, a frequent complication of chronic kidney disease. Nationally, the code matters because it affects dialysis treatment costing, facility billing workflows, and Medicare and commercial payer coverage across outpatient dialysis programs.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context around epoetin alfa use in dialysis, typical sites of administration, and what payers commonly consider when processing claims for unit-based erythropoietin products. The publication summarizes benchmarks and coverage trends relevant to hospital outpatient departments and freestanding dialysis centers, highlights typical billing considerations tied to unit dosing, and notes areas where policy updates or reimbursement guidance could influence coding practice.
This executive briefing is intended for billing professionals, dialysis administrators, and policy analysts seeking a practical, national-level summary of how HCPCS Level II code J0886 is used and reimbursed in routine dialysis care.
Billing Code Overview
HCPCS Level II code J0886 represents an injection of epoetin alfa, 1000 units, specifically indicated for end-stage renal disease (ESRD) patients on dialysis. The service type is therapeutic medication administration intended to treat anemia associated with chronic kidney disease in the dialysis population.
Typical site of service for this code is dialysis centers and other outpatient infusion or injection settings where patients receive maintenance dialysis. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with end-stage renal disease (ESRD) receiving maintenance hemodialysis three times weekly presents to the outpatient dialysis unit for a scheduled dialysis session. The patient has chronic anemia of renal disease with hemoglobin trending below target despite oral iron supplementation. The dialysis nurse prepares and administers an intravenous dose of epoetin alfa during the dialysis session, documented as J0886 (injection, epoetin alfa, 1000 units). The workflow includes verification of physician order, review of most recent hemoglobin and iron indices, medication reconciliation, informed consent for treatment, preparation under sterile conditions, administration via IV push or slow IV injection during dialysis, monitoring for immediate adverse effects (hypertension, thrombosis, flu-like symptoms), and documentation of dose, lot number, route, site, time, pre- and post-vital signs, and response. Billing is submitted to the patient’s payer using the HCPCS Level II code J0886 with any applicable modifiers to indicate service specifics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | When a clinically significant E/M visit is provided on the same day as (e.g., assessment of anemia management prior to injection). |